Sight Sciences, Inc. (SGHT) Stock Price & Analysis

Sight Sciences, Inc. (SGHT) closed at USD 9.24 on Wednesday, October 28, 2026, up 2.33% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 9.03; the Oct 28, 2026 session ranged USD 9.02–9.41 on volume of 346,162 shares. Market capitalization is $509.01M, with a 52-week range of USD 3.38–9.71 (NMS). Source: Nexqual, retrieved October 29, 2026 at 06:43 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SGHT.md

Key facts (SGHT)

• Last four reported quarters (through Jun 30, 2026): revenue $83.4M, net income -$29.8M (-35.7% margin), free cash flow -$23.3M (SEC filings).
• Insider open-market sales, last ~7 months: 12 Form 4 filings, $1.2M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $69K; 1 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 10.17 (range 8–14).
• Total return with dividends: 1Y +83.3% vs S&P 500 +13.6%; 5Y -65.7% vs S&P 500 +79.8%.
• Next earnings: 2026-11-04, EPS estimate USD -0.12, revenue estimate $23.5M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SGHT)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SGHT)

P/S 6.1x · EV/Sales 5.6x · P/B 9.6x · FCF yield -4.58% · Earnings yield -5.85% · Net cash $39.0M · EV $470M

Insider sales (SEC Form 4, open-market, last ~7 months) (SGHT)

12 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (SGHT)

1 purchase, $69K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (SGHT)

Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 10.17 (low 8, high 14).

Rating changes, last 120 days:

Total return (dividends reinvested) (SGHT)

SGHT earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

SGHT recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

SGHT revenue by business segment (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SGHT suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 4, 2026.

Companies that name SGHT in their SEC reports

SGHT company outlook (results filed Aug 5, 2026)

• “Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.”
• “(Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2026.”

Quoted word-for-word from the SEC 8-K results press release.

SGHT analyst estimates and revisions

SGHT options: expected move

Options price a move of about ±41.0% (±$3.75) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±14.9% on average.

30-day implied volatility 88.6% vs 54% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 06:43 UTC)

Technical Analysis (SGHT)

Nexqual's technical model rates SGHT "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 06:43 UTC.

Analyst Ratings (SGHT)

Wall Street analysts rate SGHT "Buy" based on 8 analysts, with a mean price target of USD 10.17 (range USD 8–14), per Nexqual as of October 29, 2026 at 06:43 UTC.

Earnings (SGHT)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 06:43 UTC.

Financials & Fundamentals (SGHT)

Source: Nexqual, October 29, 2026 at 06:43 UTC.

Financial Health Score (SGHT)

Nexqual rates Sight Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:43 UTC.

Ownership (SGHT)

Source: Nexqual, October 29, 2026 at 06:43 UTC.

Leadership (SGHT)

Sight Sciences, Inc. is led by Paul Badawi, Co-Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:43 UTC.

Major Backers & Investors (SGHT)

Notable institutional backers of Sight Sciences, Inc. include Long Focus Capital Management, LLC, Americana Partners, LLC, Pathstone Holdings, LLC, according to Nexqual as of October 29, 2026 at 06:43 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 06:43 UTC.

From Sight Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)

Key Strengths & Strategy (as disclosed to the SEC)

• Key findings indicated that a 20% increase in market share of TearCare compared to prescription dry eye medications would yield an estimated annual savings of $36.87 per member per year across all plan members in a hypothetical health plan with one million covered lives.
• In the United States, any products we sell are required to be manufactured in compliance with the FDA's Quality Management System Regulation ("QMSR"), which covers the methods used in, and the facilities used for, the design, testing, control, manufacturing, labeling, quality assurance, packaging, storage and shipping of our products.
• Our continued success depends on our ability to: Develop innovative, proprietary technology and products that can cost-effectively address significant clinical needs; Obtain and maintain regulatory clearances or approvals for the use of our products; Obtain and maintain favorable reimbursement decisions relating to the use of our products; Demonstrate clinical safety and effectiveness in our sponsored and third-party trials and studies; Successfully market and sell products.
• Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future products and product candidates, novel discoveries, product development technologies and know-how; to operate without infringing on the proprietary rights of others; and to prevent others from infringing our proprietary rights.

Partnerships

• We are party to a supply agreement with Peter's Technology (Suzhou) CO LTD. ("PTCS"), a Chinese subsidiary of Peter's Co., Ltd., a Taiwan-based contract manufacturer (as amended, the "Peter's Supply Agreement"), pursuant to which PTCS manufactures our OMNI and SION products as well as certain components of our TearCare system.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not receive, or may be delayed in receiving, necessary clearances, certifications or approvals for our future products or modifications to our current products, and failure to timely obtain or retain such clearances, certifications or approvals would adversely affect our ability to grow our business.
• We may incur significant liability if it is determined that we are promoting off-label uses of our products in violation of federal and state regulations in the United States or elsewhere.
• Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market.
• Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, financial condition and results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt